Role of probiotics in prevention of necrotizing enterocolitis in preterm neonates by S, Chandrashekar G et al.
Vol 5 | Issue 2 | Feb 2018 Indian J Child Health 112
Original Article
Role of probiotics in prevention of necrotizing enterocolitis in preterm neonates
Chandrashekar G S1, Sanchita Shettigar2, Tharun C Varghese1
From Departments of 1Paediatric and 2Microbiology, A. J. Institute of Medical Sciences, Kuntikana, Mangalore, Karnataka, India
Correspondence to: Dr. Sanchita Shettigar, Department of Microbiology, A. J. Institute of Medical Sciences, Kuntikana, 
Mangalore - 575004, Karnataka, India. Phone: +91-9449244205. Fax: 0824-2225541. E-mail: drsanchita_12@rediffmail.com
Received - 01 December 2017 Initial Review - 02 January 2018 Published Online - 26 January 2018
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in preterm newborns [1]. Despite recent advances in neonatal care, the incidence 
of NEC and the associated mortality and morbidity remain 
high [2]. NEC occurs more commonly in the premature infants. 
The incidence of NEC increases with decreasing gestational age 
and birth weight. The incidence of NEC varies among NICUs 
worldwide but ranges from 3% to 28% with an average of 7% 
in infants with birth weight <1500 g [3]. The overall mortality 
related to NEC ranges between 20 and 30 %, with the highest rate 
among infants requiring surgery [4]. The mortality rate in infants 
weighing <1500 g can be as high as 45% [5].
Both medical and surgical management play important role 
in the management of NEC, but prevention is definitely a better 
choice to reduce overall morbidity and mortality. Probiotics 
may be one of the most effective therapies for the prevention of 
NEC. It may prevent NEC by promoting colonization of gut with 
beneficial organism, preventing colonization by harmful bacteria, 
improving the gut maturity and mucosal barrier function, and 
modulating immune system.
Many western studies have indicated the beneficial effects of 
probiotics in preterm neonates without any significant adverse 
effects [6-8]. Studies based on the use of probiotics in preterm 
neonates in the prevention of NEC from India are limited [9,10]. 
Therefore, this study has been undertaken to assess the efficacy 
of probiotics in prevention of NEC in preterm neonates and its 
role on secondary outcomes such as length of hospital stay, age of 
onset of NEC, regaining birth weight, and time to reach full feed.
MATERIALS AND METHODS
This prospective randomized controlled interventional study was 
conducted in a tertiary care teaching hospital from March 2014 
to August 2015, for 1½ year. The study was carried out after 
obtaining prior approval from the Institutional Ethical Committee. 
An informed consent was taken from parents. Clinically stable 
preterm neonates ≤34 weeks of gestation admitted to neonatal 
unit were included in the study. Sick preterm neonates not on oral 
feeds or newborns with major congenital anomaly were excluded 
from the study. Based on an estimated reduction in the incidence 
of NEC from 11% in non-intervention group to 5% with treatment, 
to achieve the power of 80% and α error of 5%, we calculated that 
a minimum of 140 sample size was required. Fig. 1 shows the 
study inclusion flowchart.
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Detailed history and examination, with special emphasis to 
known risk factors associated with NEC, was carried out. The 
recruited newborns that were fulfilling the above criteria were 
randomized into intervention group and control group by simple 
random sampling method. The intervention group had received 
probiotics within 1st 10 days of life when the infant is ready for 
enteral feeds and continued for a minimum period of 7 days or till 
the corrected gestational age of 35 weeks. Probiotics were mixed 
with expressed breast milk and fed twice daily in infants with 
study group. The control group was fed with milk alone.
The progress of the neonate giving special importance to feed 
intolerance (defined as the presence of gastric aspirate in the 
amount that was more than half of the previous feeding, or with 
abdominal distension by monitoring abdominal girth or occult 
blood in stools) was carried out every day. If the diagnosis of 
NEC was established, feeding as well as probiotics was stopped 
and the newborn was assigned a stage according to Modified 
Bell’s Staging Criteria [11]. Probiotic sachets were used in this 
study amounted each sachet of 1gm, which was a combination 
of probiotics not <1.25 billion cells of Lactobacillus acidophilus, 
Lactobacillus rhamnosus, Bifidobacterium longum, and 
Saccharomyces boulardii.
The data analysis was performed using the SPSS version 17 
and MicroSoft Excel sheet. Parametric data were presented as 
mean±standard deviations. Relationships between variables were 
analyzed using Chi-square test and independent sample t-test. 
The p<0.05 was considered statistically significant.
RESULT
During 1½ year of the study period, a total number of 145 preterm 
newborns were included in the analysis. They were assigned 
randomly to interventional group (72) and control group (73). Of 
these, one newborn from intervention group could not receive a 
minimum of 7 days of probiotics and hence excluded (Fig. 1). Two 
newborns from the control group were discharged against medical 
advice, and one patient from each group had withdrawn consent 
before completion of the study. Table 1 presents the baseline 
characteristics of population studied. There was no significant 
difference between two groups in demographic profile (p>0.05). 
There were no large for gestational age babies in both groups.
The risk factors associated with NEC had shown in Table 2. 
There was a slightly higher number of newborns treated for patent 
ductus arteriosus (PDA), who received packed RBC transfusion 
and were given mixed feeding in probiotics group. However, 
none of the risk factors is statistically significant in terms of a 
number of preterm newborns assigned in each group (p>0.05). 
This means that risk factors for NEC had not influenced outcomes 
of the study in either group. All babies with PDA were treated 
with syrup Ibuprofen.
The efficacy of probiotics in reducing the incidence of NEC 
has shown in Table 3. Of 140 newborns studied, 10 (7.14%) had 
developed NEC. The incidence of NEC in probiotics group and 
control group was 2.86% and 11.43%, respectively, which was 
statistically significant (p=0.04). Seven of 10 (70%) newborns 
had stage I NEC. Three babies in control group had stage 2 NEC 
but none in probiotics group. There were no cases of NEC of 
stage ≥III in either group.
Table 4 summarizes the effect of probiotics on the secondary 
outcomes. There was no significant difference in age in the 
diagnosis of NEC and the age of gaining of birth weight between 
two groups. However, there was a statistically significant 
difference in duration of hospital stay and time to reach full feed 
between interventional and control group (p<0.001).
Overall culture-proven sepsis rate was 20%. As shown in 
Table 5, there was no difference in the incidence of sepsis between 






Male 38 (54.29) 41 (58.57)
Female 32 (45.71) 29 (41.43) 
Gestational 
age (weeks) 
<28 2 (2.86) 3 (4.29)
28–32 35 (50.00) 36 (52.43)
>32 33 (47.14) 31 (44.29)
Birth weight (g) 
<1000 2 (2.86) 3 (4.29)
1000–1500 41 (58.57) 38 (54.29)
>1500 27 (38.57) 29 (41.43)
Weight for gestation 
SGA* 10 (14.29) 14 (20.00)
AGA* 60 (85.71) 56 (80.00)
Mode of delivery 
Vaginal 42 (60.00) 38 (54.29)
Cesarean 28 (40.00) 32 (45.71)
Mural status 
Inborn 63 (90.00) 59 (84.29)
Out born 7 (10.00) 11 (15.71)
*SGA ‑ Small for gestational age, AGA ‑ Appropriate for gestational age
Al l  NICU Admissions during the 
s tudy period (n=910)
Exclus ion: GA >34 weeks 
n=512, Sick preterm 
n=245 and Congenital 
anomaly n=8
Included in analysis  
n=145
Control  group    n=73
DAMA  n=2, Consent 
withdrawn   n=1
Control  group: Final 
analysis  n=70   
Probioc group  n=72
Not completed 7 
days   n=1, Consent 
withdrawn  n=1
Probioc group:  
Final analysis  n=70
Figure 1: Study inclusion flowchart. GA: Gestational age, 
DAMA: Discharged against medical advice
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probiotics and control group (p=0.673; relative risk [RR] 1.15, 
95% confidence interval [CI]: 0.593–2.243). Staphylococcus 
aureus 13 (46%) were the most common bloodstream isolates, 
followed by Klebsiella pneumonia 9 (32%), Acinetobacter 
baumannii 3 (11%), and Candida species 3 (11%). There was no 
significant difference between two groups in organism isolated. 
There was almost equal risk of death among preterm neonates 
with NEC (one from probiotic group and 4 from control group 
with NEC). This means that the use of probiotics did not reduce the 
overall mortality rate (p=0.209; RR 0.25, 95% CI: 0.029–2.18).
DISCUSSION
NEC is one of the life-threatening emergencies in premature 
neonates. Data obtained from large multicenter study showed 
a mean prevalence of 7% in infants weighing <1500 g with an 
estimated mortality of 15–30% [12]. Most of the infants in whom 
NEC develops were previously fed, and the disease usually 
occurs after a week after initiation of enteral feeding. However, 
orally fed probiotics may be a promising new approach for the 
prevention of NEC in preterm neonates.
Wang et al. conducted a meta-analysis of 20 updated 
randomized controlled trials of probiotics use in preterm infants 
with very low birth weight in reducing NEC and mortality, and 
they had found that the overall incidence of NEC of stage 2 or 
higher was 3.0% and 7.4%, respectively, for probiotics group 
and control group [7]. Another meta-analysis conducted by 
Yang et al. concluded that, regardless of gestational age and NEC 
stage, probiotic supplementation could significantly reduce the 
risk of NEC in preterm infants. Analysis also indicated that such 
supplementation did not increase the incidence risk of sepsis or 
mortality. Further, the study showed that probiotics use may have 
no adverse effect on normal feeding and growth [13].
However, the results of the study performed by Sari et al. [14] 
and Dani et al. [15] suggested no significant difference in reduction 
of NEC or death in preterm neonates <33 weeks or birth weight 
<1500 g. The use of single probiotics agent rather than multiple 
agents may explain the smaller treatment effect in their study.
In the present study, the incidence of NEC in probiotics 
group was much lower compared to control group (2.86% vs. 
11.43%) which was statistically significant (p=0.04). Although 
there were no significant differences in the initial presentation 
of NEC between the two groups, those in the study group who 
did develop NEC had less severe disease, based on Bell’s staging 
criteria. Similar observation was made by Arora et al. (1.33% 
vs. 16%; p=0.001) who used a similar strain of probiotics as we 
did in our study [9]. Another study by Bin-Nun et al. who used 
different strain of probiotics had found reduced incidence (4% vs. 
16.4%; p=0.031) and severity of NEC (Bell’s criteria 2.3 ±0.5 vs. 
1.3±0.5; p=0.005) in probiotics supplemented group [16].
In our study, there was no significant difference in age in the 
diagnosis of NEC and age of gaining birth weight between two 
groups which was similar to other study [16]. However, there 
was a statistically significant difference in duration of hospital 
stay and time to reach full feed between interventional and 
control group (p<0.001). Similarly, Chowdhury et al. reported 
significantly shorter duration of hospital stay (15.82±2.94 days 
vs. 19.57±4.26 days; p<0.001) and shorter age of achievement 
of full feeding (14.88±3.15 vs. 18.80±4.32 days; p<0.001) in the 
study group [17].
In our study, there was no significant difference in the incidence 
of overall mortality (p=0.209; RR 0.25, 95% CI: 0.029–2.18) and 
sepsis rate (p=0.673; RR 1.15, 95% CI: 0.593–2.243) between the 
two groups. Sreenivasa et al. reported (28 of 100 vs. 42 of 100, 
p=0.038) significantly lower incidence of sepsis in probiotics 
group [10]. In contrast, Lin et al. found that probiotics use may 
increase the risk of sepsis in infants weighing <750 g [18].
In the present study, there was no significant difference 
in demographic and clinical variables of two groups studied. 
Antenatal risk factors also did not differ significantly between 
two groups. We included only clinically stable neonates in our 
study. Hence, our data cannot be applied to sick preterm neonates, 
though NEC is more common in these sick newborns.





PROM 16 (22.86) 18 (25.71)
Incomplete or no 
antenatal steroids*
6 (8.56) 8 (11.43)
Reversal of diastolic 




15 (21.43) 18 (25.71)
Birth asphyxia 4 (5.71) 3 (4.28)
PDA treatment 11 (15.71) 9 (12.86)
UAC 6 (8.57) 4 (5.71)
Packed RBC 
transfusion
13 (18.57) 10 (14.29)
Type of feeding 
Only breast milk 52 (74.29) 57 (81.43)
Mixed (breast and 
formula)
11 (15.71) 7 (10.00)
Only formula 7 (10.00) 6 (8.57)
PROM: Premature rupture of membrane, PDA: Patent ductus arteriosus, UAC: 
Umbilical artery catheterization, RBC: Red blood cell, USG: Ultrasonography
*Incomplete course of antenatal steroid is defined as mother had received antenatal 
steroids <24 h or >7 days before delivery. NEC: Necrotizing enterocolitis
Table 3: Incidence NEC
Bell’s 
staging
Probiotics (n=70) Control (n=70) Total (n=140)
No NEC 68 (97.14) 62 (88.57) 130 (92.86)
Stage IA 1 (1.42) 5 (7.14) 6 (4.29)
Stage IB 1 (1.42) 0 1 (0.71)
Stage IIA 0 2 (2.86) 2 (1.43)
Stage IIB 0 1 (1.42) 1 (0.71)
Stage IIIA 0 0 0
Stage IIIB 0 0 0
NEC: Necrotizing enterocolitis
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CONCLUSION
Probiotics supplementation reduced the incidence and severity of 
NEC in the preterm neonates. It was also associated with shorter 
duration of hospital stay and faster achievement of full oral feeds. 
There was no significant difference in mean age of onset of NEC, 
mortality, and sepsis rate.
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Table 4: Effect of probiotics on secondary outcomes
Characteristics (Mean±SD) p
Probiotics group (n=70) days Control (n=70) days
Length of hospital stay 15.62±2.84 23.54±3.43 <0.001
Age of onset of NEC 10.52±2.14 9.98±2.62 0.18
Time to reach full feed* 15.82±3.15 20.22±2.14 <0.001
Birth weight regained 12.53±1.24 12.84±2.22 0.31
*Full enteral feeding was defined as an enteral milk intake of 150 ml/kg/day. SD: Standard deviation, NEC: Necrotizing enterocolitis
Table 5: Effect of probiotics on sepsis and mortality
Characteristics Probiotics group (n=70) Control (n=70) Total (n=140)
Sepsis 15 (21.43) 13 (18.57) 28 (20.0)
Mortality 1 (1.43) 4 (5.71) 5 (3.57)
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